期刊文献+

可溶性Flt-1在子痫前期患者胎盘组织中的变化及意义 被引量:3

Alteration and potential role of soluble fms-like tyrosine kinase receptor 1 in preeclampsia
下载PDF
导出
摘要 目的研究可溶性血管内皮生长因子受体1(solublefms-liketyrosinekinasereceptor1,sFlt-1)mRNA在子痫前期患者胎盘组织中的表达与定位,探讨其与子痫前期的关系。方法通过半定量RT-PCR及原位杂交方法分别检测子痫前期患者和健康孕妇胎盘组织中sFlt-1mRNA的表达及定位。结果正常胎盘组织和子痫前期胎盘组织中均存在sFlt-1mRNA,子痫前期胎盘组织中sFlt-1mRNA表达明显高于正常胎盘组织(P<0.01)。sFlt-1mRNA主要分布在胎盘绒毛滋养细胞及血管内皮细胞胞浆内。结论胎盘组织中sFlt-1的高表达可能参与了子痫前期的病理生理过程。 Objective:To investigatethe expression and location of soluble fms-like tyrosine kinase receptor 1 (sFlt-1) mRNA in placenta of preeclampsia and its role in preeclampisa pathophysiology. Methods: Semi-quantitative RT-PCR was carried out to detect the level of sFlt-1 mRNA in placental tissue of 10 preeclampsia (study group) and 10 normotensive pregnancies (control group); sFlt-1 mRNA was pinpointed by in situ hybridization. Results: The sFlt-1 mRNA was expressed in both preeclampsia and normal placenta. However, its levels were significantly higher in the former than in the latter (P<0.01); sFlt-1 mRNA was located in trophocyte of placenta by in situ hybridization. Conclusion: Higher expression of sFlt-1 may be associated with the pathogenesis of preeclampsia.
出处 《中国优生与遗传杂志》 2005年第6期19-21,18,共4页 Chinese Journal of Birth Health & Heredity
基金 国家自然科学基金资助项目(30070787)
关键词 可溶性血管内皮生长因子 子痫前期 原住杂交 Preeclampsia sFlt-1 In situ hybridization
  • 相关文献

参考文献10

  • 1林其德.妊娠高血压综合征病因学研究进展与展望[J].中华妇产科杂志,2003,38(8):471-473. 被引量:138
  • 2李东红,姜锋,姚元庆,杨梦庚,郑维国.妊娠高血压综合征胎盘组织差异表达基因的筛选与确定[J].中华围产医学杂志,2004,7(4):201-205. 被引量:7
  • 3Dawn E, Stephen K, Yulong He, et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation[J]. Biol Reprod,1998,59(6):1540-1548. 被引量:1
  • 4Chen H, Ikeda U, Shimpor M, et al. Inhibition of vascular endothelial growth factor activity by transfection with the FLT-1 gene[J]. J Cardiovasc Pharmacol, 2000, 36(4): 498-502. 被引量:1
  • 5Richard L, Kendall, Kenneth A, et al. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor[J]. Proc Natl Acad Sci USA, 1993, 90: 10705-10709. 被引量:1
  • 6Roeckl W, Hecht D, Sztajer H, et al. Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2[J]. Exp Cell Res, 1998, 241(1): 161-170. 被引量:1
  • 7Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fins-like tyrosine kinase 1(sFlt-1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia[J]. J Clin Invest, 2003, 111: 649-652. 被引量:1
  • 8Levision Rj, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia[J]. Anticancer Res, 2003,23(2): 1159-1161. 被引量:1
  • 9周彩存,谈立松,唐亮,粟波.可溶性VEGF受体FLT-1克隆、表达及其对血管生成的抑制作用[J].中国肿瘤生物治疗杂志,2002,9(1):15-18. 被引量:4
  • 10Sugimoto H, Hamano Y, Charytan D, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1(sFlt-1) induces proteinuria[J]. J Biol Chem, 2003 Apr 11,278(15):12605-12608. 被引量:1

二级参考文献20

  • 1徐承熊 韩锐.MTT法测定药物对癌细胞杀伤作用的选择.抗癌药物研究与实验技术[M].北京:北京医科大学和协和大学出版社,1997.284-286. 被引量:1
  • 2Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest,2003,111:649-658. 被引量:1
  • 3Sugimoto H, Hamano Y, Charytan D, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor (sFlt-1) induces proteinuria. J Biol Chem,2003,278:12605-12608. 被引量:1
  • 4Vaillant P, David E, Constant I, et al. Validity in nulliparas of increased beta-human chorionic gonadotrophin at mid-term for predicting pregnancy-induced hypertension complicated with proteinuria and intrauterine growth retardation. Nephron,1996,72:557- 被引量:1
  • 5Smith GC, Stenhouse EJ, Crossley JA, et al. Early pregnancy levels of pregnancy-associated plasma protein A and the risk of intrauterine growth restriction, premature birth, preeclampsia,and stillbirth. J Clin Endocrinol Metab, 2002, 87: 1762-1767. 被引量:1
  • 6Takemasa I, Higuchi H, Yamamoto H, et al. Construction of preferential cDNA microarray specialized for human colorectal carcinoma: molecular sketch of colorectal cancer. Biochem Biophys Res Commun, 2001, 285: 1244-1249. 被引量:1
  • 7Diatchenko L, Lau YF, Campell AP, et al. Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries. Proc Natl Acad Sci,1996,93:6025-6030. 被引量:1
  • 8Bussolati B, Dunk C, Grohman M, et al. Vascualr endothelial growth factor receptor-1 modulates vascular endothelial growth factor mediated angiogenesis via nitric oxide. Am J Pathol,2001,159:993-1008. 被引量:1
  • 9Livingston JC, Chin R, Haddad B, et al. Reductions of vascular endothelial growth factor and placenta growth factor concentrations in severe preeclampsia. Am J Obstet Gynecol,2000,183:1554-1557. 被引量:1
  • 10Sharkey AM, Charnock-Jones DS, Boocock CA, et al. Expre-ssion of mRNA for vascular endothelial growth factor in human placenta. J Reprod Fertil,1993,99:609-615. 被引量:1

共引文献144

同被引文献15

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部